echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [Attention] The third domestic product!

    [Attention] The third domestic product!

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of sunitinib malate capsules for production of category 4, and it is expected to be approved in the near future, sprinting into the third domestic market.


    Sunitinib is a multi-target receptor tyrosine kinase inhibitor developed by Pfizer.


    Terminal sunitinib sales in public medical institutions in China

    Source: Mi Nei.


    In recent years, the domestic market for sunitinib has continued to expand.


    Application status of 4 types of imitation of sunitinib malate capsules

    Source: One-click search on Mi Nei.


    At present, a total of 5 pharmaceutical companies in the domestic market have submitted applications for the listing of sunitinib malate capsules.


    Source: Mi Neiwang database, NMPA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.